Regulation of PRMT5–MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Regulation of PRMT5–MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 116, Issue 36, Pages 17990-18000
Publisher
Proceedings of the National Academy of Sciences
Online
2019-08-23
DOI
10.1073/pnas.1901323116
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer
- (2019) Nicholas C. Turner et al. JOURNAL OF CLINICAL ONCOLOGY
- CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought
- (2018) Mary E. Klein et al. CANCER CELL
- Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance
- (2018) Claire A. Martin et al. INTERNATIONAL JOURNAL OF CANCER
- Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing
- (2018) Sarah V. Gerhart et al. Scientific Reports
- CDK4 inhibition diminishes p53 activation by MDM2 antagonists
- (2018) Anusha Sriraman et al. Cell Death & Disease
- The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial
- (2018) Ben O'Leary et al. Cancer Discovery
- Arginine Methylation: The Coming of Age
- (2017) Roméo S. Blanc et al. MOLECULAR CELL
- Cancer drug addiction is relayed by an ERK2-dependent phenotype switch
- (2017) Xiangjun Kong et al. NATURE
- Targeting MDM4 Splicing in Cancers
- (2017) Boris Bardot et al. Genes
- An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma
- (2016) Jessica L.F. Teh et al. CANCER RESEARCH
- Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6
- (2016) A. Yoshida et al. CANCER RESEARCH
- Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer
- (2016) Maria Teresa Herrera-Abreu et al. CANCER RESEARCH
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
- (2016) Massimo Cristofanilli et al. LANCET ONCOLOGY
- Treating cancer with selective CDK4/6 inhibitors
- (2016) Ben O'Leary et al. Nature Reviews Clinical Oncology
- Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
- (2016) C Yang et al. ONCOGENE
- Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5
- (2016) Konstantinos J. Mavrakis et al. SCIENCE
- MTAPdeletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells
- (2016) Gregory V. Kryukov et al. SCIENCE
- MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis
- (2016) Katya Marjon et al. Cell Reports
- The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond
- (2015) Nicole Stopa et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma
- (2015) M. E. Olanich et al. CLINICAL CANCER RESEARCH
- Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma
- (2015) T. MAHGOUB et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
- (2015) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Co-targeting BRAF and cyclin dependent kinases 4/6 for BRAF mutant cancers
- (2015) Vipin Yadav et al. PHARMACOLOGY & THERAPEUTICS
- Targeting Mdmx to treat breast cancers with wild-type p53
- (2015) S Haupt et al. Cell Death & Disease
- Targeting CDK4 and CDK6: From Discovery to Therapy
- (2015) C. J. Sherr et al. Cancer Discovery
- HTSeq--a Python framework to work with high-throughput sequencing data
- (2014) S. Anders et al. BIOINFORMATICS
- Antiproliferative Effects of CDK4/6 Inhibition in CDK4-Amplified Human Liposarcoma In Vitro and In Vivo
- (2014) Y.-X. Zhang et al. MOLECULAR CANCER THERAPEUTICS
- Loss ofCDKN2Aexpression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines
- (2014) Richard J. Young et al. Pigment Cell & Melanoma Research
- voom: precision weights unlock linear model analysis tools for RNA-seq read counts
- (2014) Charity W Law et al. GENOME BIOLOGY
- featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
- (2013) Y. Liao et al. BIOINFORMATICS
- The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma
- (2013) K. E. Sheppard et al. CLINICAL CANCER RESEARCH
- Regulation of constitutive and alternative splicing by PRMT5 reveals a role for Mdm4 pre-mRNA in sensing defects in the spliceosomal machinery
- (2013) M. Bezzi et al. GENES & DEVELOPMENT
- Structure of the Arginine Methyltransferase PRMT5-MEP50 Reveals a Mechanism for Substrate Specificity
- (2013) Meng-Chiao Ho et al. PLoS One
- Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors
- (2012) Jeffry L. Dean et al. CELL CYCLE
- Mdm2 and MdmX partner to regulate p53
- (2012) Xinjiang Wang et al. FEBS LETTERS
- MDM4 is a key therapeutic target in cutaneous melanoma
- (2012) Agnieszka Gembarska et al. NATURE MEDICINE
- Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
- (2012) Lawrence N Kwong et al. NATURE MEDICINE
- Crystal structure of the human PRMT5:MEP50 complex
- (2012) S. Antonysamy et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Versatility of PRMT5-induced methylation in growth control and development
- (2011) Vrajesh Karkhanis et al. TRENDS IN BIOCHEMICAL SCIENCES
- Nuclear Cyclin D1/CDK4 Kinase Regulates CUL4 Expression and Triggers Neoplastic Growth via Activation of the PRMT5 Methyltransferase
- (2010) Priya Aggarwal et al. CANCER CELL
- Pharmacologic Inhibition of Cyclin-Dependent Kinases 4 and 6 Arrests the Growth of Glioblastoma Multiforme Intracranial Xenografts
- (2010) K. Michaud et al. CANCER RESEARCH
- Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure
- (2010) J L Dean et al. ONCOGENE
- Inducible and reversible gene silencing by stable integration of an shRNA-encoding lentivirus in transgenic rats
- (2008) M. J. Herold et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now